STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

VBLT VASCULAR BIOGENICS LIMITED StockScouter® Report

8

StockScouter® Score

VASCULAR BIOGENICS LIMITED, a micro cap growth company in the healthcare sector, is expected to outperform the market over the next six months with average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The enterprise value-to-sales ratio is much lower than the average for comparably-sized companies in the StockScouter universe. Very Positive
  • Earnings growth in the past year has accelerated moderately compared to earnings growth in the past three years. Positive
  • Short-term relative price momentum exhibits moderate strength. Postive/Neutral

 

Concerns

  • The multi-period measure of relative price change and consistency is well below average. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that micro cap stocks will be out of favor, growth stocks will be out of favor, and healthcare stocks will be out of favor.

Expected Risk/Return

Progress: 60% done.
Progress: 100% done.
Low
High

Core Model Grades

C
C
A
N/A

Previous Ratings

9
5
5